Summary
A report is presented based on the biochemical and immunochemical studies of various tissues from a 15-year-old boy with a neuronopathic form of Gaucher's disease. Qualitative and quantitative lipid analyses revealed a storage of glucosylceramide. The striking feature was that, employing the usual assay methods, a normal activity of the lysosomal enzyme glucosylceramidase was revealed, despite massive lipid accumulation. Immunochemical assays of hepatic and splenic tissue extracts from this atypical Gaucher's patient disclosed the absence of A1 activator protein, which is necessary for the enzymic degradation of glucosylceramide in vivo. This is the second documented case of a patient presenting with glucosylceramide activator protein deficiency.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brady RO, Kanfer JN, Shapiro D (1965) Metabolism of glucocerebroside II. Evidence for an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 18:221–225
Choy FYM, Davidson RG (1980) Gaucher disease. III. Substrate specificity of glucocerebrosidase and the use of nonlabeled natural substrates for the investigation of patients. Am J Hum Genet 32:670–680
Christomanou H (1980) Niemann-Pick disease, type C: evidence for the deficiency of an activating factor stimulating sphingomyelin and glucocerebroside degradation. Hoppe-Seyler's Z Physiol Chem 361:1489–1502
Christomanou H, Kleinschmidt T (1985) Isolation of two forms of an activator protein for the enzymic sphingomyelin degradation from human Gaucher spleen. Biol Chem Hoppe-Seyler 366:245–256
Christomanou H, Aignesberger A (1986a) Two heat-stable low-molecular-mass proteins stimulating the enzymic sphingomyelin degradation isolated from human Gaucher and normal spleen. In: Freysz L, Dreyfus H, Massarelli R, Gatt S (eds) Enzymes of lipid metabolism II. Plenum Press, New York, pp 353–360
Christomanou H, Aignesberger A, Linke RP (1986b) Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant. Biol Chem Hoppe-Seyler 367:879–890
Christomanou H, Aignesberger A, Herschkowitz N, Wiesmann UN (1988) Etiology of a new identified Gaucher disease variant without glucosylceramidase defect. In: Salvayre R, Douste-Blazy L, Gatt S (eds) Enzymes of lipid metabolism III. Plenum Press, New York, pp 89–97
Conzelmann E, Sandhoff K (1978) AB variant of infantile GM2 gangliosidosis. Deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2. Proc Natl Acad Sci USA 75:3979–3983
Conzelmann E, Sandhoff K (1979) Purification and characterization of an activator protein for the degradation of glycolipids GM2 and GA2 by hexosaminidase A. Hoppe-Seyler's Z Physiol Chem 360:1837–1849
Fischer G, Jatzkewitz H (1978) The activator of cerebroside-sulfatase. A model of the activation. Biochim Biophys Acta 528:69–76
Folch J, Lee M, Sloane-Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497–509
Fürst W, Machleidt W, Sandhoff K (1988) The precursor of sulfatide activator protein is processed to three different proteins. Biol Chem Hoppe-Seyler 369:317–328
Gaucher PCE (1882) De L'épithéliome primitif de la rate. Thesis, Paris
Gonzalez-Sastre F, Pámpols T, Sabater J (1974) Infantile Gaucher's disease: a biochemical study. Neurology 24:162–167
Ho MW, O'Brien JS (1971) Gaucher's disease: deficiency of “acid” β-glucosidase and reconstitution of enzyme activity in vitro. Proc Natl Acad Sci USA 68:2810–2813
Inui K, Emmet M, Wenger DA (1983) Immunological evidence for deficiency in an activator protein for sulfatide sulfatase in a variant form of metachromatic leukodystrophy. Proc Natl Acad Sci USA 80:3074–3077
Kleinschmidt T, Christomanou H, Braunitzer G (1987) Complete amino-acid sequence and carbohydrate content of the naturally occurring glucosylceramide activator protein (A1 activator) absent from a new human Gaucher disease variant. Biol Chem Hoppe-Seyler 368:1571–1578
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
O'Brien JS, Kretz KA, Dewji N, Wenger DA, Esch F, Fluharty AL (1988) Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus. Science 241:1098–1101
Peters SP, Coyle P, Glew RH (1976) Differentiation of a β glucocerebrosidase from β-glucosidase in human tissues using sodium taurocholate. Arch Biochem Biophys 175:569–582
Skoog WA, Beck WS (1956) Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leucocytes. Blood 11:436–454
Stevens RL, Fluharty AL, Kihara H, Kaback MM, Shapiro LJ, Marsh B, Sandhoff K, Fischer G (1981) Cerebroside sulfatase activator deficiency induced metachromatic leucodystrophy. Am J Hum Genet 33:900–906
Svennerhom L, Dreborg S, Erikson A, Groth CG, Hillborg PO, Hakansson G, Nilsson O, Tibblin E (1982) Gaucher disease of the Norrbottnian type (type III). Phenotypic manifestations. In: Desnick RJ, Gatt S, Grabowski GA (eds) Gaucher disease: a century of delineation and research. Alan R Liss, New York, pp 67–94
Wenger DA, Clark C, Sattler M, Wharton C (1978) Synthetic substrate β glucosidase activity in leukocytes: a reproducible method for the identification of patients and carriers of Gaucher's disease. Clin Genet 13:145–153
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Christomanou, H., Chabás, A., Pámpols, T. et al. Activator protein deficient Gaucher's disease. Klin Wochenschr 67, 999–1003 (1989). https://doi.org/10.1007/BF01716064
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01716064